Results 161 to 170 of about 711,939 (323)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. [PDF]

, 2019
The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive genomic profiling was performed to evaluate the frequency of genomic biomarkers of ICI ...
Ali, Siraj M, Ang, Celina, Fabrizio, David, Goodman, Aaron, Klempner, Samuel J, Kurzrock, Razelle, Madison, Russell, Millis, Sherri Z, Ross, Jeffrey S, Severson, Eric A, Suh, James   +10 more
core   +1 more source

Disruption of NF‐κB‐Mediated Copper Homeostasis Sensitizes Breast Cancer to Cuproptosis

Advanced Science, EarlyView.
This study reveals a feedback mechanism regulating copper homeostasis, in which copper directly interacts with TAK1 to activate NF‐κB signaling, while NF‐κB transcriptionally suppresses copper transporter (CTR1) expression. These findings highlight a promising therapeutic strategy for breast cancer by combining NF‐κB inhibitors with copper chelators or
Xiaomei Zhang, Yaqing Su, Weixiong Yang, Zimin Song, Zicheng Sun, Xueji Wu, Jianwen Chen, Bing Gao, Zekang Wang, Lei Wang, Qiwei Jiang, Lang Bu, Jingting Li, Ying Lin, Wei Xie, Jie Li, Jianping Guo   +16 more
wiley   +1 more source

Autophagy-related long non-coding RNA MIR210HG plays a therapeutic role in hepatocellular carcinoma

Discover Oncology
Objective This study aimed to investigate the role of the autophagy-related long noncoding RNA (lncRNA) MIR210HG in hepatocellular carcinoma and its potential as a therapeutic target.
Chaoqun Zhang, Dianxing Sun, Huifang Zhou, Chao Liu, Jie Ruan, Jiwen Kang, Ying Xie   +6 more
doaj   +1 more source

Antibody To Hepatitis B Core Antigen In Patients With Hepatocellular Carcinoma

, 1977
Yasuhiko Kubo, Kunio Okuda, Masaharu Hashimoto, Yoshikazu Nagasaki, H Ebata, Yukio Nakajima, Hirotaka Musha, Koshi Sakuma, Hachiro Ohtake   +8 more
openalex   +1 more source

Excessive alpha-fetoprotein concentrations in hepatocellular carcinoma. [PDF]

, 1977
A Amery, William C. Alston, J. Kohn, W F White   +3 more
openalex   +1 more source

The Composite Antiadhesion Barrier Facilitated Fibroblast Autophagy Activation for Tendon Repair

Advanced Science, EarlyView.
Synthesis of an innovative three‐layer composite antiadhesion barrier (plasmid DNA@E–H–E′) is schematically illustrated, highlighting its reactive‐oxygen‐species‐responsive, unidirectional interleukin‐37 delivery to enhance fibroblast autophagy, thereby effectively preventing tendon adhesion and promoting scarless tendon repair.
Zhenyu Sun, Jingwen Liu, Liang Chen, Zhen Wang, Fei Wang, Shen Liu   +5 more
wiley   +1 more source

Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study identified that STK33 may serve as a target of Bufalin, which induces the degradation of STK33 and inhibits the growth of TNBC. Furthermore, STK33 is highly expressed in TNBC and enhances TNBC cell proliferation by phosphorylating and stabilizing CCAR1.
Shilong Jiang, Junyan Liu, Hui Li, Chan Zou, Xiaoya Wan, Rong Gong, Ting Jiang, Changxin Zhong, Zonglin Chen, Zewu Zhu, Dongsheng Cao, Yan Cheng   +11 more
wiley   +1 more source

Reptilase test in cirrhosis and hepatocellular carcinoma. [PDF]

, 1977
Ronald D. Barr
openalex   +1 more source

TWF2 Drives Tumor Progression and Sunitinib Resistance in Renal Cell Carcinoma through Hippo Signaling Suppression

Advanced Science, EarlyView.
Twinfilin actin‐binding protein (TWF2) is upregulated in sunitinib‐resistant renal cell carcinoma (RCC) cells, where it interacts with YAP and protects YAP from degradation. Stabilized YAP translocates into the nucleus and activates transcription of target genes, promoting RCC progression and drug resistance.
Liangmin Fu, Wuyuan Liao, Youyan Tan, Hansen Lin, Kun Ye, Xinwei Zhou, Mingjie Lin, Kangbo Huang, Minyu Chen, Jietao Wei, Haoqian Feng, Yuhang Chen, Jinwei Chen, Bohong Guan, Shan Li, Zhengkun Zhang, Anze Yu, Zihao Feng, Lizhen Zhang, Guannan Shu, Jun Lu, Wei Chen, Yihui Pan, Jiefeng Yang, Junhang Luo, Li Luo   +25 more
wiley   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

Advanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang   +8 more
wiley   +1 more source